Jonathan Wygant Biography and Net Worth

CAO of Veracyte

Jonathan Wygant is Chief Accounting Officer at Veracyte. He oversees all aspects of the company’s global accounting operations, financial reporting, and tax functions. Mr. Wygant has nearly 20 years of experience leading accounting operations for various healthcare and biotechnology companies. Prior to joining Veracyte in February 2022, he served as Corporate Controller at Biosplice Therapeutics, Inc., a clinical-stage biotechnology company, where he led all finance, accounting and reporting functions. Prior to that, Mr. Wygant was Chief Financial Officer at Cibus Global, LLC., an agricultural biotechnology company. He also served as Vice President, Controller and Chief Accounting Officer at Alere, Inc., a $2.5B point-of-care diagnostics company that was acquired by Abbott. Prior to that, Mr. Wygant served as Senior Vice President, Controller and Chief Accounting Officer at CareFusion, a $3.5B global medical technology and manufacturing company that was acquired by BD (Becton, Dickinson and Company). Mr. Wygant began his career in accounting with PricewaterhouseCoopers. He holds a Bachelor of Accountancy from the University of San Diego.

What is Jonathan Wygant's net worth?: The estimated net worth of Jonathan Wygant is at least $1.91 million as of December 3rd, 2024. Mr. Wygant owns 40,270 shares of Veracyte stock worth more than $1,909,201 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Wygant may own. Learn More about Jonathan Wygant's net worth.
How old is Jonathan Wygant?: Mr. Wygant is currently 53 years old. There are 5 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on Jonathan Wygant's age.
How do I contact Jonathan Wygant?: The corporate mailing address for Mr. Wygant and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Jonathan Wygant's contact information.
Has Jonathan Wygant been buying or selling shares of Veracyte?: Jonathan Wygant has not been actively trading shares of Veracyte during the past quarter. Most recently, Jonathan Wygant sold 956 shares of the business's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $43.36, for a transaction totalling $41,452.16. Following the completion of the sale, the chief accounting officer now directly owns 40,270 shares of the company's stock, valued at $1,746,107.20. Learn More on Jonathan Wygant's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Phillip Febbo (Insider), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Annie Mcguire (SVP), Marc Stapley (CEO), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 132,722 shares worth more than $5,646,695.43. The most recent insider tranaction occured on December, 4th when SVP Annie Mcguire sold 1,422 shares worth more than $67,260.60. Insiders at Veracyte own 1.4% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 12/4/2025.

Jonathan Wygant Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/3/2024	Sell	956	$43.36	$41,452.16	40,270
11/27/2024	Sell	5,032	$42.89	$215,822.48	42,313

Jonathan Wygant Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Today's Range

Now: $47.41

$46.02

$47.78

50 Day Range

MA: $39.11

$33.44

$49.38

2 Week Range

Now: $47.41

$22.61

$50.71

Volume

895,484 shs

Average Volume

974,443 shs

Market Capitalization

$3.75 billion

P/E Ratio

124.77

Dividend Yield

N/A

Beta

1.83

Jonathan Wygant Biography and Net Worth

What is Jonathan Wygant's net worth?

How old is Jonathan Wygant?

How do I contact Jonathan Wygant?

Has Jonathan Wygant been buying or selling shares of Veracyte?

Who are Veracyte's active insiders?

Are insiders buying or selling shares of Veracyte?